Responding to a report from the UK's National Audit Office that was presented by the Committee of Public Accounts which, among other things, said that huge savings could be made by physicians prescribing generic medicines (Marketletter January 21), the Association of the British Pharmaceutical Industry and the Ethical Medicines Industry Group have gone on the counter-attack, arguing the importance of innovative medicines.
UK lags Europe in use of new medicines
New, innovative medicines are under-used by the National Health Service, not over-prescribed as claimed by the CPA, the ABPI said. In fact, the UK lags behind the rest of Europe in the uptake of modern medicines and - if companies did not provide relevant, ethical information to doctors about them - the problem would be worse still. The assertion that NHS doctors prescribe too many branded medicines is contradicted by the fact that 82% of all prescriptions are written generically and the UK is bottom of the league compared with other, similar countries in prescribing modern medicines, it noted.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze